EMAP-II/AIMP1 Protein, Mouse, Recombinant (His)

The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.

Pack Size	Availability	Price/USD
100 μg	5 days	$ 371.00
500 μg	5 days	$ 1,490.00
1 mg	5 days	$ 2,480.00

Pack Size

Availability

Price/USD

Quantity

100 μg

5 days

$ 371.00

500 μg

5 days

$ 1,490.00

1 mg

5 days

$ 2,480.00

Description

Species	Mouse
Expression System	E. coli
Tag	N-His
Accession Number	P31230
Synonyms	p43, SCYE1, HLD3, EMAP-II, AIMP1, EMAP-2
Construction	Recombinant Mouse EMAP-II/AIMP1 Protein is expressed from E.coli with His tag at the N-Terminus. It contains Ala2-Lys310.[Accession \|P31230]
Protein Purity	> 95% as determined by Tris-Bis PAGE
Molecular Weight	The protein has a predicted MW of 35.1 kDa. The protein migrates to 42-46 kDa based on Tris-Bis PAGE result.

Endotoxin	Less than 1EU per μg by the LAL method.
Formulation	Supplied as 0.22μm filtered solution in 20mM Tris, 500mM NaCl, 10% Glycerol (pH 8.0).
Stability & Storage	Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Research Background	The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.